KHIDI to Support Clinical Trials and Commercialization for 12 Korean Companies

Domestic biohealth companies are set to target the global market using the Texas Medical Center (TMC), the world's largest medical and life sciences complex in the United States, as a strategic base.


On the 26th, at a business agreement ceremony held in Houston, USA, Younghoon Jung, Planning Director of the Korea Health Industry Development Institute, is taking a commemorative photo with Ashley MacPhail, Chief of External Cooperation and Administration at Texas Medical Center. Korea Health Industry Development Institute

On the 26th, at a business agreement ceremony held in Houston, USA, Younghoon Jung, Planning Director of the Korea Health Industry Development Institute, is taking a commemorative photo with Ashley MacPhail, Chief of External Cooperation and Administration at Texas Medical Center. Korea Health Industry Development Institute

View original image

On June 29, the Ministry of Health and Welfare and the Korea Health Industry Development Institute announced that they will expand their support hub, which had previously focused on the Cambridge Innovation Center (CIC) in Boston on the U.S. East Coast, to Houston in the central United States. Based at TMC, they plan to support Korean companies with local office space, networking, and commercialization initiatives.


To this end, on June 26 in Houston, the Korea Health Industry Development Institute signed separate memoranda of understanding (MOUs) with the Texas Medical Center and the Texas chapter of the Korean American Medical Association (KAMA Texas).


Through these agreements, the Korea Health Industry Development Institute will establish a foundation to fully leverage TMC's clinical and medical networks—the largest in the world—for the support of Korean biohealth companies. The institute will provide hands-on support for local settlement and global commercialization by facilitating office space for Korean companies at the TMC Innovation Factory and by connecting them with TMC experts and local networking opportunities.


This agreement is seen as laying the groundwork for Korean companies to directly utilize TMC's extensive clinical, research infrastructure, and medical network, which are the largest in the world. Previously, at the 'K-Biohealth Connect & Development (C&D) Center' established in the Boston CIC in 2022, 45 Korean biohealth companies received support for office space and operations.


Going forward, the Korea Health Industry Development Institute plans to provide support for Korean companies to move into the Innovation Factory, TMC’s space for innovative companies, as well as connect them with local expert networks and offer investment and commercialization support programs. This year, 12 companies will receive initial support, participating in local networking and business development programs to refine their strategies for entering the U.S. market.


KAMA Texas, which signed the agreement on the same day, is a leading Korean American physicians' organization in Texas and plans to provide practical support for the overseas expansion of Korean companies through close connections with the local medical community. In particular, they will match company needs with association-affiliated specialists and provide one-on-one clinical consulting by medical specialty, thereby assisting in product validation and the development of strategies for entering the U.S. market.


Younghoon Jung, Director of Planning at the Korea Health Industry Development Institute, stated, "This agreement is meaningful in that it establishes a cooperative foundation for Korean companies to work with U.S. medical institutions and expert networks to validate products and pursue commercialization. We will continue to expand our support so that our companies can strengthen their competitiveness in the global market."



William F. McKeon, President and CEO of TMC, commented, "Korea continues to introduce innovative technologies in digital health, biotechnology, and medical devices, solidifying its position as a global powerhouse in the biohealth industry. We look forward to building strategic partnerships with Korea’s innovative companies and providing opportunities for exchange with world-class clinicians and researchers."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing